SAN DIEGO, Nov. 4, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today announced that the Company's third quarter financial results will be released on Monday, November 10, 2014. Company management will host a conference call on Monday, November 10, 2014, at 8:30 a.m. Eastern Time to discuss the financial results and other recent corporate highlights.
To participate by telephone, please dial 877-407-9210 (Domestic) or 201-689-8049 (International). The conference ID number is 13594918. The live audio webcast can be accessed via the Investors section of the Company's website at www.apricusbio.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for 90 days following the live call.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines to meet the needs of patients. The Company's lead product, Vitaros®, for the treatment of erectile dysfunction, is approved in Europe and Canada and commercialized in several countries in Europe. Apricus' marketing partners for Vitaros® include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires Majorelle. The Company's second-generation Vitaros room temperature device is under development and is expected to enhance the product's commercial value. The Company recently initiated a Phase 2a trial for RayVa™, the Company's product candidate for the treatment of Raynaud's phenomenon. Femprox®, the Company's product candidate for the treatment of female sexual interest/arousal disorder, has successfully completed an approximately 400-subject proof-of-concept study. The Company is currently seeking a strategic partner for Femprox. In October 2014, Apricus gained U.S. development and commercialization rights for fispemifene, a selective estrogen receptor modulator, in Phase 2 development.
For further information on Apricus, visit http://www.apricusbio.com.
CONTACT: Steve Martin Apricus Biosciences Chief Financial Officer email@example.com (858) 222-8041 Institutional Investors: Angeli Kolhatkar firstname.lastname@example.org Media: Justin Jackson email@example.com Burns McClellan (212) 213-0006 Retail Investors: Chris Eddy, David Collins firstname.lastname@example.org Catalyst Global (212) 924-9800
Source:Apricus Biosciences, Inc.